Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 747,900 shares, an increase of 13,498.2% from the November 15th total of 5,500 shares. Approximately 38.2% of the shares of the company are short sold. Based on an average daily volume of 2,990,000 shares, the days-to-cover ratio is currently 0.3 days.

Cyclerion Therapeutics Price Performance

Shares of CYCN opened at $3.57 on Friday. Cyclerion Therapeutics has a 1 year low of $1.27 and a 1 year high of $9.47. The company’s fifty day moving average is $2.69 and its two-hundred day moving average is $2.77.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.